Skip to main content

Advertisement

SpringerLink
Log in

Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: Results of the Pan-American Collaborative Retina Study (PACORES) group

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to report the 5-year outcomes of treatment-naive eyes with cystoid macular edema secondary to central retinal vein occlusion treated with intravitreal bevacizumab in routine clinical practice.

Methods

We conducted multicenter retrospective non-comparative case series of 102 eyes. The main outcome measured was the change in best-corrected visual acuity (BCVA) at 5 years. Secondary outcomes included the number of injections and the change in CMT at 5 years.

Results

At 5 years, the mean BCVA improved from 1.22 ± 0.58 (Snellen 20/428) at baseline to 1.00 ± 0.68 logMAR (Snellen 20/200; p < 0.0001). At 5 years, 48 (47%) eyes had a gain of ≥ 3 lines, 41 (40.2%) eyes remained within 3 lines and 13 (12.7%) eyes had a loss of ≥ 3 lines of BCVA. The CMT improved from 740 ± 243 to 322 ± 179 µm (p < 0.0001). At 5 years, 59 (57.8%) eyes had a completely dry SD-OCT. Patients received a total of 10.6 ± 6.1 (range 6–27) injections. Baseline BCVA (p < 0.0001) and the duration of symptoms prior to initial anti-VEGF injection (p = 0.0274) were the only predictive factors for BCVA at 5 years.

Conclusions

After 5 years with an average of 10.6 injections, there was a mean gain of 0.22 logMAR. In addition, more eyes achieved a BCVA of ≥ 20/40, gained ≥ 3 lines and less patients had a BCVA ≤ 20/200. Eyes with a better baseline BCVA and a shorter duration of symptoms were more likely to achieve better BCVA at 5 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

The data have not been shared on a repository.

References

  1. Campochiaro PA, Hafiz G, Shah SM et al (2008) Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 16(4):791–799

    Article  CAS  Google Scholar 

  2. Pe’er J, Folberg R, Itin A et al (1998) Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105(3):412–416

    Article  CAS  Google Scholar 

  3. Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331(22):1480–1487

    Article  CAS  Google Scholar 

  4. Noma H, Funatsu H, Mimura T et al (2011) Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Curr Eye Res 36(3):256–263

    Article  CAS  Google Scholar 

  5. Tolentino MJ, Miller JW, Gragoudas ES et al (1996) Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103(11):1820–1828

    Article  CAS  Google Scholar 

  6. Hofman P, van Blijswijk BC, Gaillard PJ et al (2001) Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. Arch Ophthalmol 119(6):861–866

    Article  CAS  Google Scholar 

  7. Wroblewski JJ, Wells JA 3rd, Adamis AP et al (2009) Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 127(4):374–380

    Article  CAS  Google Scholar 

  8. Brown DM, Campochiaro PA, Bhisitkul RB et al (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594–1602

    Article  Google Scholar 

  9. Epstein DL, Algvere PV, von Wendt G et al (2012) Benefit from bevacizumab for macular edema in central retinal vein occlusion: 12-month results of a prospective, randomized study. Ophthalmology 119(12):2587–2591

    Article  Google Scholar 

  10. Brown DM, Heier JS, Clark WL et al (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155(3):429–437

    Article  CAS  Google Scholar 

  11. Hutton D, Newman-Casey PA, Tavag M et al (2014) Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period. Health Aff (Millwood) 33(6):931–939

    Article  Google Scholar 

  12. Anothaisintawee T, Leelahavarong P, Ratanapakorn T, Teerawattananon Y (2012) The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand’s pharmaceutical benefit package. Clinicoecon Outcomes Res 4:361–374

    Article  Google Scholar 

  13. Soheilian M, Garfami KH, Ramezani A et al (2012) Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina 32(2):314–321

    Article  CAS  Google Scholar 

  14. Solaiman KA, Diab MM, Dabour SA (2013) Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema. Retina 33(8):1623–1629

    Article  CAS  Google Scholar 

  15. Arevalo JF, Sanchez JG, Wu L et al (2009) Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American collaborative retina study group at 24 months. Ophthalmology 116(8):1488–1497

    Article  Google Scholar 

  16. Wu L, Arevalo JF, Berrocal MH et al (2010) Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months. Retina 30(7):1002–1011

    Article  Google Scholar 

  17. Scott IU, VanVeldhuisen PC, Ip MS et al (2017) Effect of bevacizumab versus aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA 317(20):2072–2087

    Article  CAS  Google Scholar 

  18. Bressler NM (2017) Treatment of macular edema due to central retinal vein occlusion: another score for repackaged bevacizumab. JAMA 317(20):2067–2069

    Article  Google Scholar 

  19. Heier JS, Clark WL, Boyer DS et al (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: 2-year results from the COPERNICUS study. Ophthalmology 121(7):1414–1420

    Article  Google Scholar 

  20. Campochiaro PA, Brown DM, Awh CC et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(10):2041–2049

    Article  Google Scholar 

  21. Korobelnik JF, Holz FG, Roider J et al (2014) Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: 1-year results of the phase 3 GALILEO study. Ophthalmology 121(1):202–208

    Article  Google Scholar 

  22. Gerding H (2017) Intravitreal anti-VEGF treatment in central retinal vein occlusion (CRVO): a meta-analysis of 1 year results. Klin Monbl Augenheilkd 234(4):546–550

    Article  CAS  Google Scholar 

  23. Lin J, Gibbons A, Smiddy WE (2020) Cost-utility of anti-VEGF treatment for macular edema secondary to central retinal vein occlusion. Ophthalmol Retina 5(7):656–663

    Article  Google Scholar 

  24. Hykin P, Prevost AT, Vasconcelos JC et al (2019) Clinical effectiveness of intravitreal therapy with ranibizumab versus aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion: a randomized clinical trial. JAMA Ophthalmol 137:1256

    Article  Google Scholar 

  25. Epstein DL, Algvere PV, von Wendt G et al (2012) Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 119(6):1184–1189

    Article  Google Scholar 

  26. Heier JS, Campochiaro PA, Yau L et al (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119(4):802–809

    Article  Google Scholar 

  27. Campochiaro PA, Sophie R, Pearlman J et al (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121(1):209–219

    Article  Google Scholar 

  28. Spaide RF (2013) Prospective study of peripheral panretinal photocoagulation of areas of nonperfusion in central retinal vein occlusion. Retina 33(1):56–62

    Article  Google Scholar 

  29. Kornhauser T, Schwartz R, Goldstein M et al (2016) Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: bevacizumab for RVO long-term follow-up). Graefes Arch Clin Exp Ophthalmol 254(5):835–844

    Article  CAS  Google Scholar 

  30. Bajric J, Bakri SJ. 2015 Outcomes of patients initially treated with intravitreal bevacizumab for central retinal vein occlusion: long-term follow-up. Semin Ophthalmol pp 1–6

  31. Spooner K, Fraser-Bell S, Hong T, Chang AA (2019) Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors. BMJ Open Ophthalmol 4(1):e000249

    Article  Google Scholar 

  32. Gale R, Gill C, Pikoula M et al (2020) Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2020-317306

    Article  PubMed  Google Scholar 

  33. Scott IU, VanVeldhuisen PC, Ip MS et al (2018) Comparison of monthly versus treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: secondary outcomes from the SCORE2 randomized clinical trial. JAMA Ophthalmol 136(4):337–345

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Asociados de Macula Vitreo y Retina de Costa Rica, Primer Piso, Torre Mercedes, Paseo Colón, San José, Costa Rica

    Lihteh Wu & Dhariana Acon

  2. Department of Ophthalmology, Illinois Eye and Ear Infirmary, University of Illinois Chicago School of Medicine, Chicago, IL, USA

    Lihteh Wu

  3. Department of Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico

    Maria H. Berrocal

  4. Oftalvist Clinic, Valencia, Spain

    Roberto Gallego-Pinazo & Rosa Dolz-Marco

  5. Oftalmologos Contreras, Lima, Peru

    Jose A. Roca

  6. Department of Ophthalmology, Vision Institute, Federal University of Sao Paulo, Sao Paulo, Brazil

    Mauricio Maia

  7. Fundación Hospital Nuestra Señora de la Luz, Mexico City, Mexico

    Sergio Rojas

  8. Department of Ophthalmology, University of Buenos Aires, Buenos Aires, Argentina

    Marcelo Zas

  9. Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA

    J. F. Arevalo

  10. L.V.Prasad Eye Institute, Hyderabad, India

    Jay Chhablani

  11. Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA, USA

    Jay Chhablani

Authors
  1. Lihteh Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dhariana Acon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria H. Berrocal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberto Gallego-Pinazo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rosa Dolz-Marco
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jose A. Roca
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mauricio Maia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sergio Rojas
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marcelo Zas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. F. Arevalo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jay Chhablani
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation and data collection were performed by all the authors. Data analysis was performed by LW and DA. The first draft of the manuscript was written by DA, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Lihteh Wu.

Ethics declarations

Conflict of interest

Dhariana Acon, Mauricio Maia, Jose A Roca, Sergio Rojas, Roberto Gallego-Pinazo and Jay Chhablani declare that they do not have conflict of interest. Dr. Lihteh Wu has received lecture fees from Bayer and Quantel Medical. Dr. Rosa Dolz-Marco has received lecture fees from Heidelberg Engineering. Dr. Maria H Berrocal and Dr Marcelo Zas have received lecture fees from ALCON. Dr. J Fernando Arevalo Abbvie: Consultant/Advisor; GENENTECH: Consultant/Advisor; Springer SBM LLC: Patents/Royalty; THEA Laboratories: Consultant/Advisor; Topcon Medical Systems Inc.: Grant Support.

Consent to participate

Exemption of informed consent was obtained by being a retrospective case series that used de-identified patient data. IRB approval was obtained at all centers.

Consent to publish

Exemption of informed consent was obtained by being a retrospective case series that used de-identified patient data.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, L., Acon, D., Berrocal, M.H. et al. Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: Results of the Pan-American Collaborative Retina Study (PACORES) group. Int Ophthalmol 42, 951–958 (2022). https://doi.org/10.1007/s10792-021-02077-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-021-02077-5

Keywords

Search

Navigation